Floatz logo

Vaxigrip

Tolerance

Medical University of WarsawvaccinePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Tolerance cohort.

Asset / SponsorPhaseRating
Ertugliflozin
Getz Pharma
Phase 4BB
Acetylsalicylic Acid
Northern California Institute of Research and Education
Phase 2B
Hydrochlorothiazide
Northern California Institute of Research and Education
Phase 2B
ATENOLOL
Northern California Institute of Research and Education
Phase 2B
SIMVASTATIN
Northern California Institute of Research and Education
Phase 2B

View all 10 →

Same molecule, other indications

Vaxigrip is also rated in:

influenzaDormant
BB
Indicative ·
65 / 100
View asset →
Pregnancy; InfectionDormant
BB
Indicative ·
65 / 100
View asset →
infectious diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →